Rachel Levine Nominated as U.S. Assistant Health Secretary
WEDNESDAY, Jan. 20, 2021 -- Rachel Levine, M.D., a transgender woman, has been nominated by President-elect Joe Biden to serve as assistant secretary for health at the U.S. Department of Health and Human Services.
If confirmed by the Senate, Levine would be the first openly transgender federal official in a Senate-confirmed role, according to Biden's transition team, CBS News reported.
Levine is the secretary of health for Pennsylvania and is currently leading the state's response to the COVID-19 pandemic.
"Dr. Rachel Levine will bring the steady leadership and essential expertise we need to get people through this pandemic -- no matter their zip code, race, religion, sexual orientation, gender identity, or disability -- and meet the public health needs of our country in this critical moment and beyond," Biden said in a statement, CBS News reported. "She is a historic and deeply qualified choice to help lead our administration's health efforts."

© 2021 HealthDay. All rights reserved.
Posted: January 2021
Read this next
Two Cases of SARS-CoV-2 Variant P.1 Identified in Minnesota
FRIDAY, March 5, 2021 -- Two cases of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant P.1 identified in Minnesota are described in a report published in...
Three Modes of Transmission Explain Most Giardiasis Outbreaks
FRIDAY, March 5, 2021 -- Three main modes of transmission have been identified for giardiasis outbreaks in the United States in 2012 to 2017, although a single transmission mode...
Six in 10 Heart Failure Patients Readmitted Within One Year
FRIDAY, March 5, 2021 -- Among heart failure patients, hospital readmission is frequent and often occurs in the early postdischarge period, according to a study published online...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.